These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 36217836)

  • 21. A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment.
    Focosi D; Casadevall A
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
    Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
    J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak.
    You J; Tian J; Wu H; Kang W; Wen J; Xu H; Shi W; Wang Z; Wei H; Du Y; Li X; Mu G; Zhou M; Gu Z; Qu J
    Expert Rev Anti Infect Ther; 2023; 21(12):1365-1371. PubMed ID: 37855094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
    Fomina DS; Lebedkina MS; Iliukhina AA; Kovyrshina AV; Shelkov AY; Andreev SS; Chernov AA; Dolzhikova IV; Kruglova TS; Andrenova GV; Tukhvatulin AI; Shcheblyakov DV; Karaulov AV; Lysenko MA; Logunov DY; Gintsburg AL
    Front Immunol; 2023; 14():1259725. PubMed ID: 37928549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.
    Yan VKC; Yang Y; Wan EYF; Lai FTT; Chui CSL; Li X; Wong CKH; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Drug Saf; 2024 Oct; 47(10):1025-1037. PubMed ID: 38916712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
    Bender Ignacio RA; Chew KW; Moser C; Currier JS; Eron JJ; Javan AC; Giganti MJ; Aga E; Gibbs M; Tchouakam Kouekam H; Johnsson E; Esser MT; Hoover K; Neytman G; Newell M; Daar ES; Fischer W; Fletcher CV; Li JZ; Greninger AL; Coombs RW; Hughes MD; Smith D; Wohl DA;
    JAMA Netw Open; 2023 Apr; 6(4):e2310039. PubMed ID: 37099295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
    Angotzi F; Petrella M; Berno T; Binotto G; Bonetto G; Branca A; Carraro M; Cavaretta CA; Cellini A; D'Amore F; Forlani L; Gianesello I; Gurrieri C; Imbergamo S; Lessi F; Maroccia A; Mazzetto F; Pavan L; Pezone S; Piazza F; Pravato S; Ruocco V; Scapinello G; Vianello F; Zambello R; Zatta I; Zoletto S; Padoan A; Trentin L; Visentin A
    Front Oncol; 2023; 13():1212752. PubMed ID: 37427126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients.
    Benotmane I; Velay A; Gautier-Vargas G; Olagne J; Obrecht A; Cognard N; Heibel F; Braun-Parvez L; Keller N; Martzloff J; Perrin P; Pszczolinski R; Moulin B; Fafi-Kremer S; Thaunat O; Caillard S
    Am J Transplant; 2022 Nov; 22(11):2675-2681. PubMed ID: 35713984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study.
    Lendacki FR; Li L; Forrest GN; Jordan L; Zelinski C; Black SR; Ison MG; Seo JY
    Transpl Infect Dis; 2024 Feb; 26(1):e14194. PubMed ID: 37987112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tixagevimab-cilgavimab as pre-exposure prophylactic treatment against SARS-CoV-2 in kidney transplantation patients].
    Bravo González-Blas L; Menéndez García N; Fernández Prada M; Gago Fraile M; Suárez Fernández ML; Ridao Cano N
    Nefrologia (Engl Ed); 2024; 44(3):396-401. PubMed ID: 38331599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
    Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
    Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
    [No Abstract]   [Full Text] [Related]  

  • 32. Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19.
    Clegg LE; Stepanov O; Schmidt H; Tang W; Zhang H; Webber C; Cohen TS; Esser MT; Någård M
    Antimicrob Agents Chemother; 2024 May; 68(5):e0158723. PubMed ID: 38534112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.
    Minopoulou I; Tascilar K; Corte G; Mutlu MY; Schmidt K; Bohr D; Hartmann F; Manger K; Manger B; Korn K; Kleyer A; Simon D; Harrer T; Schett G; Fagni F
    Rheumatology (Oxford); 2024 May; 63(5):1377-1383. PubMed ID: 37531288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tixagevimab and Cilgavimab Administration for Hemodialysis Patients at Community-Based Dialysis Centers in Singapore as Pre-Exposure Prophylaxis for SARS-CoV-2 Infection.
    Khan BA; Pagsinohin M; Lu LM; Tan P; Teo R
    Cureus; 2023 Jul; 15(7):e41297. PubMed ID: 37539406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
    Tuffy KM; Ahani B; Aksyuk AA; Avila M; Brady T; Kijak GH; Koh G; Levin MJ; Roe TL; Schuko N; Thissen J; Ustianowski A; Zhang T; Kelly EJ; Streicher K
    J Infect Dis; 2023 Oct; 228(8):1055-1059. PubMed ID: 37280116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis.
    Elias LB; Jaber A; Manzano M; Leekoff M; Sylvester A; Tremblay MA
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.
    Schiaroli E; Gidari A; Brachelente G; Bicchieraro G; Spaccapelo R; Bastianelli S; Pierucci S; Busti C; Pallotto C; Malincarne L; Camilloni B; Falcinelli F; De Socio GV; Villa A; Mencacci A; Francisci D
    J Clin Virol; 2023 Nov; 168():105584. PubMed ID: 37778220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
    Hobbs FDR; Montgomery H; Padilla F; Simón-Campos JA; Kim K; Arbetter D; Padilla KW; Reddy VP; Seegobin S; Streicher K; Templeton A; Viani RM; Johnsson E; Koh GCKW; Esser MT
    Infect Dis Ther; 2023 Sep; 12(9):2269-2287. PubMed ID: 37751015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
    Ntanasis-Stathopoulos I; Filippatos C; Gavriatopoulou M; Malandrakis P; Eleutherakis-Papaiakovou E; Spiliopoulou V; Syrigou RE; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Kastritis E; Dimopoulos MA; Terpos E
    Diseases; 2023 Sep; 11(3):. PubMed ID: 37754319
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19].
    Zhuravleva MV; Chulanov VP; Gagarina JV; Shabalina EA
    Ter Arkh; 2023 Feb; 95(1):66-77. PubMed ID: 37167117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.